A Phase 2 interventional study of LCI699 and Eplerenone in Hypertension, sponsored by Novartis. Completed at 38 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-02.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.
Among the 227 studies in Hypertension by Novartis, this one is the 140th largest by enrollment of the 222 interventional ones that give a count, is one of 25 that started in 2008, is one of 29 in phase 2, and was the 155th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Arab Emirates
Ages 18–99
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Japan, Singapore
Ages 18+
By country, each count listing its studies:
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 109 · Phase 4 67
First in 1989; this study’s year is marked. 25 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 309 across the 222 interventional studies, 813 across the 4 observational. Of the 219 that completed or were terminated, 88 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
3 of the studies in Hypertension by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07465666Novartis PharmaceuticalsA Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 227 studies in Hypertension by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study assessed the blood pressure effect, safety and tolerability of LCI699 compared to placebo and eplerenone in participants with resistant hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following a 2-week placebo run-in period, participants received LCI699 0.25 mg, capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
Drug: LCI699
Following a 2-week placebo run-in period, participants received LCI699 1 mg, capsules, orally, once daily (QD), with or without food for up to 8 weeks.
Drug: LCI699
Following a 2-week placebo run-in period, participants received LCI699 0.5 mg, capsules, orally, BID, with or without food for up to 4 weeks, followed by LCI699 1 mg, capsules, orally, BID with or without food for up to 4 weeks.
Drug: LCI699
Following a 2-week placebo run-in period, participants received eplerenone 50 mg, capsules, orally, BID, with or without food for up to 8 weeks.
Drug: Eplerenone
For a 2-week placebo run-in period, followed by 8 weeks of the treatment period, participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food.
Drug: LCI699-matching Placebo · Drug: Eplerenone-matching Placebo
LCI699 oral capsules
Eplerenone oral capsules
LCI699-matching placebo oral capsules
Eplerenone-matching placebo oral capsules
Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF)
Arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and country as factors and Baseline MSSBP as a covariate.
Time frame: Baseline, Week 8
Change From Baseline in MSDBP at Week 8 LOCF
Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
Time frame: Baseline, Week 8
Percentage of Participants With a MSSBP Response and MSSBP Control at Week 8, as Measured by Office Blood Pressure (OBP)
MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg for non-diabetic participants and \<130mHg for diabetic participants.
Time frame: Week 8
Percentage of Participants With a MSDBP Response and MSDBP Control at Week 8, as Measured by OBP
MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>=10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg for non-diabetic participants and \<80mHg for diabetic participants.
Time frame: Week 8
Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8
Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate.
Time frame: Baseline, Week 8
Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8
Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
Time frame: Baseline, Week 8
Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Systolic Blood Pressure (SBP) at Week 8 LOCF, as Measured by Ambulatory Blood Pressure Measurement (ABPM)
An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate.
Time frame: Baseline, Week 8
Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime Diastolic Blood Pressure (DBP) at Week 8 LOCF, as Measured by ABPM
An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
Time frame: Baseline, Week 8
Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime SBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM
An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
Time frame: Baseline, Week 4
Change From Baseline in Mean 24 Hours, Mean Daytime and Mean Nighttime DBP in LCI699 1mg QD Versus LCI699 0.5mg BID Arm at Week 4, as Measured by ABPM
An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
Time frame: Baseline, Week 4
Number of Participants With Adverse Event (AEs), Serious Adverse Events (SAEs), Hyperkalemia, and Hyponatremia
An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality. Hyperkalemia was defined as potassium level \>5.5 millimoles per liter (mmol/L). It is the medical term that describes a potassium level that's higher than normal. Hyponatremia was defined as sodium level \<135 mmol/L. It is the medical term that describes a sodium level that's lesser than normal.
Time frame: AEs, Hyperkalemia, and Hyponatremia: From start of the study drug treatment up to 10 weeks; SAE: From signing of the informed consent up to 10 weeks
Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8
Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was \<500 nanomoles per liter (nmol/L) at 1 hour after the injection.
Time frame: 1-hour post-dose at Week 8
Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF
Percent change from Baseline was analyzed by ANCOVA model using PA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.
Time frame: Baseline, Week 8
Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
Percent change from Baseline was analyzed by ANCOVA model using plasma renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.
Time frame: Baseline, Week 8
Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
Percent change from Baseline was analyzed by ANCOVA model using active renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.
Time frame: Baseline, Week 8
Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF
Percent change from Baseline was analyzed by ANCOVA model using percent ratio of PA to PRA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.
Time frame: Baseline, Week 8
Participants took part in this study at 35 investigative sites in the United States and in Iceland from 22 December 2008 to 13 October 2009.
| Milestone | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| Started | 32 | 26 | 31 | 33 | 33 |
| Completed | 23 | 22 | 28 | 28 | 25 |
| Not completed | 9 | 4 | 3 | 5 | 8 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Abnormal laboratory value(s) | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Administrative problems | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 5 | 1 | 3 | 2 | 3 |
Arterial blood pressure (BP) determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an analysis of covariance model (ANCOVA) with treatment and country as factors and Baseline MSSBP as a covariate.
| mmHg | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF) | -11.4 ± 2.96 | -13.1 ± 3.24 | -12.5 ± 2.96 | -18.7 ± 2.92 | -8.8 ± 2.87 |
Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
| mmHg | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in MSDBP at Week 8 LOCF | -4.5 ± 1.72 | -6.0 ± 1.88 | -6.1 ± 1.72 | -7.7 ± 1.69 | -4.8 ± 1.66 |
MSSBP response was defined as the percentage of participants with a MSSBP \<140 mmHg or a \>=20 mmHg reduction from baseline reduction from baseline. MSSBP control was defined as the percentage of participants with a MSSBP \<140 mmHg for non-diabetic participants and \<130mHg for diabetic participants.
| percentage of participants | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| MSSBP Response | 54.8 | 57.7 | 41.9 | 65.6 | 42.4 |
| MSSBP Control | 51.6 | 50.0 | 32.3 | 53.1 | 36.4 |
MSDBP response was defined as the percentage of participants with a MSDBP \<90 mmHg or a \>=10 mmHg reduction from baseline. MSDBP control was defined as the percentage of participants with a MSDBP \<90 mmHg for non-diabetic participants and \<80mHg for diabetic participants.
| percentage of participants | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| MSDBP Response | 67.7 | 73.1 | 71.0 | 71.9 | 57.6 |
| MSDBP Control | 54.8 | 65.4 | 58.1 | 56.3 | 54.5 |
Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSSBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSSBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate.
| mmHg | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID |
|---|---|---|---|
| Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSSBP at Week 8 | -11.4 ± 2.96 | -13.1 ± 3.24 | -12.5 ± 2.96 |
Arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the American Heart Association guidelines using a calibrated standard aneroid or mercury sphygmomanometer or a calibrated standard sphygmomanometer. The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from Baseline in MSDBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
| mmHg | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID |
|---|---|---|---|
| Dose/Exposure BP Response Relationship of LCI699, as Measured by Change From Baseline in MSDBP at Week 8 | -4.5 ± 1.72 | -6.0 ± 1.88 | -6.1 ± 1.72 |
An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using ANCOVA with treatment and country as factors and Baseline MSSBP as a covariate.
| mmHg | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| 24-hour Mean SBP | -4.4 ± 3.22 | -5.7 ± 2.87 | -6.3 ± 2.47 | -15.7 ± 2.59 | -1.0 ± 2.59 |
| Daytime Mean SBP | -4.9 ± 3.29 | -6.0 ± 2.92 | -6.3 ± 2.52 | -15.7 ± 2.65 | -1.6 ± 2.65 |
| Nighttime Mean SBP | -3.2 ± 3.49 | -4.8 ± 3.13 | -7.0 ± 2.67 | -15.4 ± 2.81 | 0.4 ± 2.81 |
An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings, using an automated validated monitoring device from Baseline to Week 8. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
| mmHg | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| 24-hour Mean DBP | 1.0 ± 2.15 | -3.4 ± 1.94 | -3.7 ± 1.67 | -9.6 ± 1.74 | -0.2 ± 1.74 |
| Daytime Mean DBP | 0.6 ± 2.31 | -3.6 ± 2.06 | -3.4 ± 1.78 | -9.5 ± 1.86 | -0.8 ± 1.87 |
| Nighttime Mean DBP | 1.9 ± 2.17 | -2.5 ± 1.98 | -4.6 ± 1.69 | -9.6 ± 1.75 | 1.2 ± 1.76 |
An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour SBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24-hour period. The change from Baseline in SBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
| mmHg | LCI699 1 mg QD | LCI699 0.5 mg BID |
|---|---|---|
| 24-hour Mean SBP | -7.8 ± 2.72 | -4.7 ± 2.29 |
| Daytime Mean SBP | -8.1 ± 2.69 | -5.3 ± 2.27 |
| Nighttime Mean SBP | -6.8 ± 3.17 | -4.5 ± 2.70 |
An ABPM measured a participant's blood pressure over a 24-hour period including daytime and nighttime readings using an automated validated monitoring device from Baseline to Week 4. The 24-hour DBP was calculated by taking the mean of all ambulatory diastolic blood pressure readings for the 24-hour period. The change from Baseline in DBP was analyzed using an ANCOVA with treatment and country as factors and Baseline MSDBP as a covariate.
| mmHg | LCI699 1 mg QD | LCI699 0.5 mg BID |
|---|---|---|
| 24-hour Mean DBP | -4.3 ± 1.98 | -2.5 ± 1.67 |
| Daytime Mean DBP | -3.9 ± 2.04 | -2.6 ± 1.73 |
| Nighttime Mean DBP | -4.5 ± 2.21 | -2.8 ± 1.87 |
An AE was an adverse medical event which occurs in a participant of the study and which is not necessarily in a causal relationship with the treatment the participant receives. SAEs were AEs leading to death, are life-threatening, require hospitalizations or prolongation of hospitalizations, represent an innate malformation or a congenital abnormality. Hyperkalemia was defined as potassium level \>5.5 millimoles per liter (mmol/L). It is the medical term that describes a potassium level that's higher than normal. Hyponatremia was defined as sodium level \<135 mmol/L. It is the medical term that describes a sodium level that's lesser than normal.
| Participants | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| AE(s) | 15 | 15 | 8 | 13 | 16 |
| SAE(s) | 0 | 0 | 0 | 1 | 0 |
| Hyperkalemia [potassium level >5.5 mmol/L] | 2 | 0 | 0 | 0 | 1 |
| Hyperkalemia [potassium level ≥6.0 mmol/L] | 2 | 0 | 0 | 0 | 0 |
| Hyponatremia [sodium level <130 and ≥125 mmol/L] | 0 | 0 | 0 | 1 | 0 |
| Hyponatremia [sodium level <135 mmol/L and ≥130mmol/L] | 3 | 2 | 7 | 3 | 2 |
Serum cortisol concentrations at 1 hour after injection were measured to assess the maximum stimulated cortisol level achieved. Potential adrenal suppression was indicated if the serum cortisol concentration was \<500 nanomoles per liter (nmol/L) at 1 hour after the injection.
| Participants | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| Number of Participants With Cortisol Levels Below 500 Nmol/L at 1 Hour After Adrenocorticotropic Hormone (ACTH) Injection at Week 8 | 0 | 1 | 4 | 0 | 0 |
Percent change from Baseline was analyzed by ANCOVA model using PA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.
| percent change in aldosterone | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in Renin-Angiotensin-Aldosterone-System (RAAS) Biomarker: Plasma Aldosterone (PA) in LCI699 Compared to Eplerenone 50 mg at Week 8 LOCF | -22.3 ± 0.16 | -30.4 ± 0.17 | -53.1 ± 0.15 | 115.0 ± 0.15 |
Percent change from Baseline was analyzed by ANCOVA model using plasma renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.
| percent change in PRA | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in RAAS Biomarker: Plasma Renin Activity (PRA) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF | 41.6 ± 0.24 | 74.3 ± 0.28 | 107.7 ± 0.24 | 414.1 ± 0.22 |
Percent change from Baseline was analyzed by ANCOVA model using active renin values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.
| percent change in ARC | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in RAAS Biomarker: Active Renin (ARC) in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF | 73.1 ± 0.24 | 72.8 ± 0.27 | 156.4 ± 0.23 | 430.6 ± 0.22 |
Percent change from Baseline was analyzed by ANCOVA model using percent ratio of PA to PRA values measured at Baseline and Week 8 LOCF, with treatment and country as factors and Baseline value as the covariate. Negative percent change from Baseline shows improvement.
| percent change in ratio of PA to PRA | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID |
|---|---|---|---|---|
| Percent Change From Baseline in RAAS Biomarker: Ratio of PA to PRA in LCI699 Compared to Eplerenone 50mg at Week 8 LOCF | -46.7 ± 0.26 | -50.0 ± 0.29 | -78.3 ± 0.25 | -57.1 ± 0.23 |
Collected over AEs: From start of the study drug treatment up to 10 weeks; SAE: From signing of the informed consent up to 10 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LCI699 0.25 mg BID | 0/32 (0%) | 0/32 (0%) | 15/32 (46.9%) |
| LCI699 1.0 mg QD | 0/26 (0%) | 0/26 (0%) | 15/26 (57.7%) |
| LCI699 0.5 mg Followed by LCI699 1 mg BID | 0/31 (0%) | 0/31 (0%) | 8/31 (25.8%) |
| Eplerenone 50 mg BID | 0/33 (0%) | 1/33 (3%) | 13/33 (39.4%) |
| Placebo | 0/33 (0%) | 0/33 (0%) | 16/33 (48.5%) |
| Event | LCI699 0.25 mg BID | LCI699 1.0 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| Cerebrovascular accidentNervous system disorders | 0/32 | 0/26 | 0/31 | 1/33 | 0/33 |
| Event | LCI699 0.25 mg BID | LCI699 1.0 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo |
|---|---|---|---|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/32 | 2/26 | 0/31 | 4/33 | 0/33 |
| DizzinessNervous system disorders | 1/32 | 1/26 | 0/31 | 4/33 | 1/33 |
| DiarrhoeaGastrointestinal disorders | 3/32 | 0/26 | 0/31 | 2/33 | 1/33 |
| FatigueGeneral disorders | 0/32 | 1/26 | 1/31 | 3/33 | 2/33 |
| HyponatraemiaMetabolism and nutrition disorders | 1/32 | 0/26 | 2/31 | 2/33 | 0/33 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/32 | 0/26 | 2/31 | 0/33 | 0/33 |
| Blood cortisol decreasedInvestigations | 2/32 | 1/26 | 1/31 | 0/33 | 1/33 |
| Blood creatinine increasedInvestigations | 2/32 | 0/26 | 0/31 | 0/33 | 0/33 |
| Abdominal painGastrointestinal disorders | 0/32 | 0/26 | 0/31 | 1/33 | 2/33 |
| HeadacheNervous system disorders | 0/32 | 1/26 | 1/31 | 0/33 | 2/33 |
Full Analysis set (FAS) population included all participants who were randomized and received at least 1 dose of study drug.
| Age, Continuous(years) | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 53.6 ± 10.36 | 55.4 ± 9.58 | 57.2 ± 10.77 | 56.2 ± 7.70 | 59.8 ± 9.33 | 56.5 ± 9.69 |
| Sex: Female, Male(Participants) | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 8 | 13 | 14 | 11 | 58 |
| Male | 20 | 18 | 18 | 19 | 22 | 97 |
| Baseline Mean Sitting Systolic Blood Pressure (MSSBP)(millimeters of mercury (mmHg)) | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 152.4 ± 11.21 | 152.5 ± 9.79 | 152.2 ± 7.58 | 153.8 ± 8.92 | 153.4 ± 9.61 | 152.9 ± 9.39 |
| Baseline Mean Sitting Diastolic Blood Pressure (MSDBP)(mmHg) | LCI699 0.25 mg BID | LCI699 1 mg QD | LCI699 0.5 mg Followed by LCI699 1 mg BID | Eplerenone 50 mg BID | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 91.8 ± 11.68 | 89.2 ± 9.56 | 88.9 ± 11.89 | 89.1 ± 9.84 | 90.1 ± 11.65 | 89.8 ± 10.92 |
Ran from Dec 2008 to primary completion in Oct 2009, 9 months.
Results were first posted in Jun 2021, 11 years 7 months after primary completion. A results delay was requested in Nov 2012.
Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 9 months is below that.
Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osilodrostat